Evidence-Based Medicine
Copyright ©The Author(s) 2015.
World J Hepatol. Aug 18, 2015; 7(17): 2119-2126
Published online Aug 18, 2015. doi: 10.4254/wjh.v7.i17.2119
Table 1 Univariate analysis between survived and deceased patients at 30 d
VariablesSurvived (n = 29)Deceased (n = 23)P
Demographic
Age (yr)40 ± 9.644 ± 120.114
Alcohol consumption per day (g/d)291 ± 140302 ± 1590.809
Male, n (%)28 (97)20 (87)0.222
Laboratory parameters at admission
White blood cell counts (103/μL)17362 ± 980721772 ± 101310.11
Glucose (mg/dL)102 ± 49102 ± 610.987
Sodium (mmol/L)132 ± 6128 ± 60.019a
Total bilirubin (mg/dL)17.3 ± 8.923.6 ± 9.40.018a
AST (IU/L)172 ± 111189 ± 930.55
ALT (IU/L)66.9 ± 40.571.5 ± 330.66
γGT (IU/L)369 ± 254291 ± 1830.282
Alkaline phosphatase (IU/L)254 ± 109222 ± 1120.344
Creatinine (mg/dL)1.61 ± 1.53.5 ± 2.50.001a
INR2.05 ± 0.62.49 ± 1.480.079
Prothrombin time (s)23.14 ± 8.127.2 ± 11.20.142
Albumin (mg/dL)2.8 ± 0.52.5 ± 0.60.73
Cholesterol (mg/dL)150.8 ± 68116 ± 530.081
Triglycerides (mg/dL)222 ± 122230 ± 1780.869
Calcium (mg/dL)7.9 ± 0.77.5 ± 1.10.10
Clinical manifestations at admission
Ascites, n (%)25 (86)22 (95)0.468
Child status0.023a
Grade B, n (%)6 (20)0
Grade C, n (%)23 (80)23 (100)
Encephalophaty, n (%)0.335
None13 (45)7 (30)
Stage I4 (14)5 (22)
Stage II8 (28)10 (43)
Stage III4 (14)1 (4)
Hepatorenal syndrome, n (%)5 (17)14 (61)0.001a
Severity of liver disease at admission
MELD-Na score25.5 ± 831.9 ± 60.003a
Maddrey DFI69.4 ± 4293 ± 53.80.08
MELD32.1 ± 6.525.1 ± 2.90.79
Table 2 Univariate analysis between survived and deceased patients at 90 d
VariablesSurvived (n = 22)Deceased (n = 30)P
Demographic
Age (yr)41 ± 944 ± 110.27
Alcohol consumption per day (g/d)284 ± 148303 ± 1430.584
Male, n (%)21 (95)27 (90)0.94
Laboratory parameters at admission
White blood cell counts (103 /μL)284 ± 148303 ± 1430.584
Glucose (mg/dL)108 ± 5999 ± 490.55
Sodium (mmol/L)133 ± 5129 ± 60.03a
Total bilirubin (mg/dL)16 ± 822 ± 100.009a
AST (IU/L)192 ± 137177 ± 840.61
ALT (IU/L)103 ± 15067 ± 390.24
γGT (IU/L)577 ± 656399 ± 4800.29
Alkaline phosphatase (IU/L)281 ± 91211 ± 1050.01a
Creatinine (mg/dL)2 ± 1.83 ± 2.110.01a
INR2 ± 0.43 ± 1.30.002a
Prothrombin time (s)19 ± 428 ± 120.0003a
Albumin (mg/dL)3 ± 0.53 ± 50.54
Cholesterol (mg/dL)176 ± 90119 ± 510.01a
Triglycerides (mg/dL)240 ± 163226 ± 1620.76
Calcium (mg/dL)7.9 ± 0.87.3 ± 1.50.28
Clinical manifestations at admission
Ascites, n (%)19 (86)28 (93)0.71
Child status0.05a
Grade B, n (%)8 (37)3 (10)
Grade C, n (%)14 (63)27 (90)
Encephalophaty, n (%)0 (0)
None10 (45)0 (30)0.106
Stage I8 (37)3 (10)
Stage II4 (18)19(63)
Stage III8 (26)
Hepatorrenal syndrome, n (%)5 (22)16 (53)0.05a
Severity of liver disease at admission
MELD-Na score24.95 ± 830.9 ± 7.790.01a
Maddrey DFI68.5 ± 4288.3 ± 48.60.12
MELD22.1 ± 7.523.1 ± 3.10.28
Table 3 Variables with significance in the multivariate logistic regression analysis
SignificanceOdds ratio95%CI
30-d mortality
MELD-Na0.111.250.78-1.7
Maddrey DFI0.141.140.82-3.04
Bilirubin0.450.70.47-3.6
Creatinine0.380.310.74-1.98
INR0.410.780.68-1.52
Hepatorenal syndrome0.00111.52.7-48.11
90-d mortality
MELD-Na0.0361.191.06-1.232
Maddrey DFI0.091.030.87-1.86
Bilirubin0.230.670.65-3.56
Creatinine0.350.370.8-4.2
INR0.170.2720.78-2.6
Table 4 Clinical utility analysis at 30 and 90 d to predict mortality %
SensitivitySpecificityPositive predictive valueNegative predictive valueAccuracy
Maddrey DFI > 32
Mortality at day 309621538657
Mortality at day 909322.762.271.463.5
MELD-Na > 21
Mortality at day 308531536957.1
Mortality at day 908740666967.3